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Previewslikely in the later stages of iN reprogram-
ming. In this study, Myt1l marked a
minimal number of binding sites despite
much optimization effort in ChIP, while
its addition to the reprogramming cocktail
significantly increased reprogramming
efficiency and formation of mature neu-
rons. The low iN conversion rate (2%–
8% depending on cell type) may obscure
some interactions among Ascl1 and the
supportive transcription factors. Further-
more, it will be interesting to determine
how global transcription and epigenetic
changes occur in instances when Ascl1
is excluded from the reprogramming
cocktail.
Another stimulating question from
this study is the existence of trivalent
chromatin states or similar unknown chro-
matin states that enable accessibility to
pioneer factors in other transdifferen-
tiation contexts i.e., fibroblasts to hepa-
tocytes and cardiomyocytes, or other
known and yet undiscovered conversions512 Cell Stem Cell 13, November 7, 2013 ª2(Ladewig et al., 2013). Addressing the
binding particulars of how Ascl1 re-
cognizes the trivalent state could be
used to predict a more widespread
modus operandi of ‘‘on target’’ factors.
Taken as a whole, this study’s accom-
plishments are 2-fold. First, by delving
into the mechanism of iN reprogramming,
this study has provided more support for
the soundness of using the direct conver-
sion method, because binding patterns of
essential transcription factors resemble
those found naturally, i.e., NPCs. Second,
a trivalent chromatin state is uncovered
that further underscores the importance
of a more complex combinatorial histone
code, just like the discovery of bivalent
promoters in embryonic stem cells did
previously (Bernstein et al., 2006).REFERENCES
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Gastrointestinal toxicity of chemoradiotherapy treatment in late-stage cancer patients limits tolerable doses
and effectiveness of treatments. Zhou and colleagues in Nature (Zhou et al., 2013) suggest that activating
Robo/Slit signaling in concert with R-Spondin potentiates Wnt signaling in intestinal stem cells and drives
successful intestinal regeneration and recovery.Over the past 5 years, there has been a
dramatic increase in our understanding
of intestinal biology, including intestinal
stem cells (ISCs), homeostasis, and
transformation (reviewed in Barker
et al., 2012). Culturing intestinal epithe-
lium as organoids in vitro is now com-
mon practice for both the small intestine
and colon (reviewed in Barker et al.,
2012). This wealth of information sug-
gests that there will be an opportunityto translate this knowledge into thera-
peutic strategies for regenerative medi-
cine. One key area where our increased
understanding should yield important
insights is intestinal injury following che-
moradiotherapy. Over recent years it has
been shown that Wnt signaling is acti-
vated during intestinal regeneration
(Ashton et al., 2010) and that R-Spondin,
a Wnt agonist, can increase proliferation
of the intestine and improve recoveryafter chemoradiotherapy (Kim et al.,
2005). Despite this, R-Spondin alone
does not appear sufficiently potent to
work as a single agent to provide an
improved clinical outcome.
To address this, Zhou and colleagues
investigated pathways that may be
active within ISCs that could potentiate
R-Spondin action and discovered the
Slit/Robo pathway as a potential collabo-
rator (Figure 1). They first used fluorescent
Figure 1. Treatment with rSpon1 and rSlit2 Augments Intestinal Regeneration
Following treatment with 5-FU or irradiation, intestinal crypts are ablated, and large, proliferating crypts
appear as the intestine attempts to regenerate. TheWnt signaling pathway is activated during regeneration
and upregulates the transcription factor c-Myc, which is required for efficient proliferation. Treatment with
rSpon1 and rSlit2 following 5-FU or irradiation acts to boost Wnt signaling in Lgr5+ intestinal stem cells,
providing a pulse of proliferation that results in enhanced regeneration, increased organism survival, and
reduced tumor formation.
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Previewsin situ hybridization (FISH) to identify that
Slit2 and its receptor Robo1 were ex-
pressed in the Lgr5+ stem cells. To deter-
mine the functional requirement for Robo/
Slit, Zhou et al. examined the intestinal
phenotype of Robo1+/; Robo2+/ mice
and found that these mice had truncated
villi associated with reduced crypt prolif-
eration and fewer Lgr5+ ISCs and were
unable to grow as organoids in vitro.
Moreover, treatment with a Robo-
blocking antibody could also inhibit
proliferation, reduce the number of ISC-marker-expressing cells, and stop orga-
noid growth. Activation of Robo/Slit
signaling via the generation of a mouse
overexpressing human Slit2 (Slit2-Tg) in
the intestine caused villi hypertrophy
associated with an increase in prolifera-
tion, an increased number of Lgr5+ cells
(and other ISC-marker-positive cells),
and larger organoids in vitro.
Given this striking functional role of
Slit/Robo signaling, Zhou and colleagues
next investigated the interrelationship
between Slit/Robo and R-Spondin. Sur-Cell Stem Cell 13,prisingly, they demonstrated that rSlit2
could not only substitute for rSpon1 but
functionally cooperated with rSpon1 to
promote organoid growth. In vivo, the
number of intestinal Lgr5+ cells was
significantly increased when mice were
injected with rSpon1 and rSlit2 together,
while injection of a Robo1-blocking
antibody reduced the number of Lgr5+
cells. Given that Lgr5 and many of
the other ISC markers are Wnt target
genes, these data suggest that R-Spon-
din and Slit2 can cooperate to in-
crease intestinal stem cell function via
upregulation of Wnt signaling. How-
ever, it is worth noting that Slit2 has
previously been shown to inhibit nuclear
accumulation of b-catenin (Tseng et al.,
2010) and therefore a very important
future study is to determine how R-Spon-
din and Robo-Slit signaling cooperate
mechanistically to increase intestinal
stem cells.
Finally, Zhou et al. demonstrated the
clinical application of their findings by
attempting to reduce the massive impact
that chemoradiotherapy has on the intes-
tinal epithelium by promoting the regen-
eration process. First, wild-type mice
were exposed to 5-FU or a lethal dose
of irradiation and then treated with a
3 day pulse of rSpon1 and rSlit2. In
both experiments the treatment with
rSpon1 and rSlit2 significantly increased
intestinal regeneration, was associated
with an increase in Lgr5+ cells and prolif-
erating cells in the crypts, and extended
life span.
A major concern with upregulating Wnt
signaling for regenerative medicine is the
possibility of promoting tumorigenesis.
Deregulation of Wnt signaling has been
shown to both initiate cancer and drive
progression. The role of Wnt signaling
for tumorigenesis is particularly evident
in CRC, where 80% of tumors carry muta-
tions in the Wnt signaling pathway. These
mutations are predominantly in Apc, a
cytoplasmic protein that targets the
cotranscription factor b-catenin for
destruction and thus restrains the Wnt
pathway. A direct concern for increasing
Wnt signaling is that recent studies have
shown that other pathways such as
RAC and NF-KB, which increased the
expression of the Wnt-driven ISC signa-
ture, can also expand the cell of origin
of colorectal cancer through increased
dedifferentiation (Myant et al., 2013;November 7, 2013 ª2013 Elsevier Inc. 513
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PreviewsSchwitalla et al., 2013). To address this
Zhou and colleagues administered a
3 day pulse of rSpon1 and rSlit2 to
ApcMin/+ mice treated with DSS to accel-
erate intestinal tumor formation and
exposed to the chemotherapy agent 5-
FU. Remarkably, not only was life span
significantly increased, but this treatment
was associated with a marked decrease
in the number of intestinal tumors. In this
experiment, the 5-FU only group died
before the end of therapy, and thus it’s
hard to know whether the reduction of
tumorigenesis in the rSpon1 and rSlit2
mice was comparable with what would
have been observed with 5-FU alone.
However, it is tempting to speculate that
these results might support the ‘‘just
right’’ model for Wnt signaling during tu-
mor formation. This model suggests that
there is an optimal window of Wnt
signaling required for tumorigenesis and
that very high Wnt signaling, as induced
here by rSpon1 and rSlit2, is actually
cytotoxic and kills transformed cells (Al-
buquerque et al., 2002; Me´niel et al.,
2013). Further work is required to deter-
mine the effect of this combination on
cancer cells and normal cells; many other
epithelial cells, e.g., skin, express both
Lgr4–6 receptors and thus could be acti-
vated if they also express the ROBO re-514 Cell Stem Cell 13, November 7, 2013 ª2ceptor. Moreover, recent studies have
shown the SLIT/ROBO pathway as a
key new axis identified by the TGCA
sequencing consortia (Biankin et al.,
2012); thus, the impact of thesemutations
would be important to ascertain if pa-
tients undergoing chemoradiotherapy
were to be cotreated with rSpon1 and
rSlit2.
In summary, this work holds exciting
translational promise to alleviate the
severe side effects of chemoradiother-
apy. Moreover, the key concern of a
promotion of tumorigenesis was not
found in this preliminary study, and
there is even a possibility that there
might be a beneficial effect by over-
activating the Wnt signaling pathway
in tumor cells during chemotherapy.
Finally, given the fact that Lgr5 has
recently been found to be expressed on
many regenerating epithelial cells, e.g.,
liver, it is possible that if the Slit/Robo
pathway is also active in these cells,
there could be broad implications for
the use of rSpon1/rSlit2 treatment for
regenerative medicine.REFERENCES
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The microenvironment within the bone marrow that maintains hematopoietic stem cell (HSC) quiescence
is the subject of intense study. In a recent Nature paper, Kunisaki et al. combine imaging techniques and
computational modeling to define a novel arteriolar niche for quiescent HSCs within the bone marrow.The hematopoietic stem cell (HSC) niche
is a spatially confined unit within the
bone marrow cavity that uniquely regu-
lates the choice between HSC quies-cence and proliferation (Schofield, 1978).
In suchmicroenvironments, HSCs receive
regulatory signals from neighboring or
adjacent cells, the extracellular matrix,and soluble factors. During the past
decade, the existence of at least two
subcompartments of the HSC niche has
been considered. The endosteal niche,
